Back to top

Analyst Blog

Zacks Equity Research

Cyberonics Stands Out at Outperform

CPHD CYBX

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Apr 10, we reaffirmed our long-term Outperform recommendation on Cyberonics Inc. (CYBX - Analyst Report) based on consistent strong results and excellent growth potential. This prominent player in the neuromodulation space carries a Zacks Rank #1 (Strong Buy).

Why Outperform?

Our positive bias on Cyberonics is supported by strong growth in the U.S. on the heels of epilepsy device sales. Moreover, the company also garnered record high revenues in the overseas market on the back of double-digit growth in Europe. The sharpened focus on Japan should support the top line in the coming quarters.

According to recent statistics from U.S. Centers for Disease Control and the National Epilepsy Foundation, there exists a sizeable market opportunity in the U.S. As Cyberonics is a major player in the epilepsy market, we believe that the company will be able to sustain its market-leading growth rate. Given the prevailing underpenetration in the global market, increasing utilization and adoption of Cyberonics’ offerings should drive growth going forward.

Further, Cyberonics’ presence is not limited to the market for epilepsy treatment. The company is currently engaged in discussions with Centers for Medicare & Medicaid Services (CMS) to reconsider reimbursement coverage for VNS Therapy for all treatment-resistant depression (TRD) indications. Additionally, the company is working on VNS Therapy treatment for other indications like Obstructive Sleep Apnea (OSA) and Chronic Heart Failure (CHF). Cyberonics’ effort to strengthen its pipeline improves its growth prospects.

Additionally, Cyberonics continues to reward shareholders with attractive share repurchases. The share repurchase program will allow the company to further leverage earning power going forward.

The revision in the Zacks Consensus Estimates also reflects bullish sentiments for the ongoing and next fiscal. Over the last 60 days, the Zacks Consensus Estimate inched up 5.6% to $1.70 for fiscal 2013, reflecting annualized growth of 33.54%. For fiscal 2014, the Zacks Consensus Estimate improved 5.5% to $1.93, reflecting growth of 13.68%.

Other Stocks to Consider

Cyberonics is not the only medical device stock that warrants a look. Other industry players such as Conceptus Inc. , Cepheid Inc. (CPHD - Analyst Report) and Given Imaging Ltd. , carrying a Zacks Rank #1, are also worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%